Morgan Stanley restated their buy rating on shares of Reckitt Benckiser Group (LON:RB) in a research report sent to investors on Tuesday morning.

RB has been the subject of several other reports. Barclays reissued an equal weight rating and issued a GBX 6,450 ($84.28) target price on shares of Reckitt Benckiser Group in a research report on Tuesday, September 4th. Credit Suisse Group reissued an underperform rating on shares of Reckitt Benckiser Group in a research report on Thursday, August 23rd. Goldman Sachs Group set a GBX 7,025 ($91.79) target price on shares of Reckitt Benckiser Group and gave the stock a neutral rating in a research report on Monday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Reckitt Benckiser Group from GBX 7,000 ($91.47) to GBX 9,000 ($117.60) and gave the stock an overweight rating in a research report on Thursday, September 6th. Finally, UBS Group boosted their price objective on shares of Reckitt Benckiser Group from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a neutral rating in a research note on Monday, September 17th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 7,021.25 ($91.75).

RB stock opened at GBX 6,714 ($87.73) on Tuesday. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).

The company also recently disclosed a dividend, which was paid on Thursday, September 27th. Stockholders of record on Thursday, August 16th were paid a GBX 70.50 ($0.92) dividend. This represents a dividend yield of 1.04%. The ex-dividend date was Thursday, August 16th.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: Understanding each part of a balance sheet

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.